SRNE Financials: Sorrento Therapeutics Inc AI Analysis



Financials

SRNE Financial

Sorrento Therapeutics Inc

-54.54%

$0

At close: Jun 22, 16:00:00 GMT-4

Post-market: Jun 22, 20:00:00 GMT-4

Overview Forecast Earnings Dividends Financials

Key Stats

Prev.Close

$0.0011

Open

$0.0006

Day's Range

$0.0004 - $0.0012

52 week range

$0.0002 - $0.0985

Volume

501.6K

Avg.Volume

361.0K

Dividend yield

EPS (TTM)

-1.87

Market Cap

$275.6K

What is SRNE?

Sorrento Therapeutics, Inc. engages in the research, development, and manufacture of biopharmaceutical products. The company is headquartered in San Diego, California and currently employs 949 full-time employees. The company went IPO on 2007-01-19. The firm is engaged in developing a portfolio of next-generation treatments for cancer, infectious diseases and pain. The company is also developing Resiniferatoxin (RTX), a naturally occurring non-opioid ultra-potent transient receptor potential vanilloid-1 agonist. The Company’s proprietary fully human G-MAB antibody library and ACEA small molecule library are the pipeline of new solutions for cancer. Its diagnostics platforms include the COVIMARK lateral flow antigen test and the VIREX platform.

Features

Markets

News

Breakdown	TTM	06/30/2023	03/31/2023	12/31/2022	09/30/2022	06/30/2022
Revenue	64	15	16	15	17	11
Revenue Growth (YoY)	16%	36%	-11%	15%	42%	-15%
Cost of Revenue	35	8	5	13	8	5
Gross Profit	28	6	11	1	9	5
Selling, General & Admin	193	48	55	39	50	48
Research & Development	186	33	43	41	68	48
Operating Expenses	378	83	103	73	118	33
Other Non Operating Income (Expenses)	-4	-4	0	--	--	--
Pretax Income	-552	-107	-142	-210	-91	-220
Income Tax Expense	9	0	11	-1	-1	-1
Net Income	-548	-95	-139	-223	-89	-218
Net Income Growth	5%	-56%	248%	55%	-25%	31%
Shares Outstanding (Diluted)	551.3	551.3	549.3	484.5	451.6	402.8
Shares Change (YoY)	37%	37%	63%	56.99%	51%	37%
EPS (Diluted)	-0.99	-0.17	-0.25	-0.46	-0.2	-0.54
EPS Growth	-24%	-69%	108%	-2%	-50%	-5%
Free Cash Flow	-243	-55	-49	-72	-65	-83
Free Cash Flow Per Share	--	--	--	--	--	--
Gross Margin	43.75%	40%	68.75%	6.66%	52.94%	45.45%
Operating Margin	-546.87%	-506.66%	-575%	-473.33%	-641.17%	-245.45%
Profit Margin	-856.25%	-633.33%	-868.75%	-1,486.66%	-523.52%	-1,981.81%
Free Cash Flow Margin	-379.68%	-366.66%	-306.25%	-480%	-382.35%	-754.54%
EBITDA	-346	-75	-91	-70	-108	-26
EBITDA Margin	-540.62%	-500%	-568.75%	-466.66%	-635.29%	-236.36%
D&A For EBITDA	4	1	1	1	1	1
EBIT	-350	-76	-92	-71	-109	-27
EBIT Margin	-546.87%	-506.66%	-575%	-473.33%	-641.17%	-245.45%
Effective Tax Rate	-1.63%	0%	-7.74%	0.47%	1.09%	0.45%

Breakdown

TTM

06/30/2023

03/31/2023

12/31/2022

09/30/2022

06/30/2022

Revenue

Revenue Growth (YoY)

16%

36%

-11%

15%

42%

-15%

Cost of Revenue

Gross Profit

Selling, General & Admin

193

Research & Development

186

Operating Expenses

378

103

118

Other Non Operating Income (Expenses)

-4

Pretax Income

-552

-107

-142

-210

-91

-220

Income Tax Expense

-1

Net Income

-548

-95

-139

-223

-89

-218

Net Income Growth

-56%

248%

55%

-25%

31%

Shares Outstanding (Diluted)

551.3

549.3

484.5

451.6

402.8

Shares Change (YoY)

37%

63%

56.99%

51%

37%

EPS (Diluted)

-0.99

-0.17

-0.25

-0.46

-0.2

-0.54

EPS Growth

-24%

-69%

108%

-2%

-50%

-5%

Free Cash Flow

-243

-55

-49

-72

-65

-83

Free Cash Flow Per Share

Gross Margin

43.75%

40%

68.75%

6.66%

52.94%

45.45%

Operating Margin

-546.87%

-506.66%

-575%

-473.33%

-641.17%

-245.45%

Profit Margin

-856.25%

-633.33%

-868.75%

-1,486.66%

-523.52%

-1,981.81%

Free Cash Flow Margin

-379.68%

-366.66%

-306.25%

-480%

-382.35%

-754.54%

EBITDA

-346

-75

-91

-70

-108

-26

EBITDA Margin

-540.62%

-500%

-568.75%

-466.66%

-635.29%

-236.36%

D&A For EBITDA

EBIT

-350

-76

-92

-71

-109

-27

EBIT Margin

-546.87%

-506.66%

-575%

-473.33%

-641.17%

-245.45%

Effective Tax Rate

-1.63%

-7.74%

0.47%

1.09%

0.45%

Follow-Up Questions

What are Sorrento Therapeutics Inc's key financial statements?



According to the latest financial statement (Form-10K), Sorrento Therapeutics Inc has a total asset of $0, Net loss of $0

What are the key financial ratios for SRNE?



Sorrento Therapeutics Inc's Current ratio is 0, has a Net margin is 0, sales per share of $0.

How is Sorrento Therapeutics Inc's revenue broken down by segment or geography?



Sorrento Therapeutics Inc largest revenue segment is Cloud & Networking, at a revenue of 1,410,800,000 in the most earnings release.For geography, Americas is the primary market for Sorrento Therapeutics Inc, at a revenue of 480,900,000.

Is Sorrento Therapeutics Inc profitable?



no, according to the latest financial statements, Sorrento Therapeutics Inc has a net loss of $0

Does Sorrento Therapeutics Inc have any liabilities?



no, Sorrento Therapeutics Inc has liability of 0

How many outstanding shares for Sorrento Therapeutics Inc?



Sorrento Therapeutics Inc has a total outstanding shares of 0

Sorrento Therapeutics Inc (SRNE) Financial

SRNE Stock Price Chart

Key Stats

Prev.Close

Open

Day's Range

52 week range

Volume

Avg.Volume

Dividend yield

EPS (TTM)

Market Cap

What is SRNE?

Sorrento Therapeutics Inc (SRNE) Financial

SRNE Stock Price Chart

Key Stats

Prev.Close

Open

Day's Range

52 week range

Volume

Avg.Volume

Dividend yield

EPS (TTM)

Market Cap

What is SRNE?

SRNE Income

Follow-Up Questions

What are Sorrento Therapeutics Inc's key financial statements?

What are the key financial ratios for SRNE?

How is Sorrento Therapeutics Inc's revenue broken down by segment or geography?

Is Sorrento Therapeutics Inc profitable?

Does Sorrento Therapeutics Inc have any liabilities?

How many outstanding shares for Sorrento Therapeutics Inc?